01.02.2010 • News

Siegfried to Introduce Functional Organization

Siegfried has announced its intention to replace its current two-division structure with a functional organization effective from March 1. The company said it will increasingly market its two core capabilities - the development and production of active pharmaceutical ingredients and finished dosage forms - as a single package.

"Siegfried ... is capable of providing both the chemical synthesis of active pharmaceutical ingredients and production of finished dosage forms," CEO Rudolf Hanko said. "Our new organizational structure will make allowance for this fact."

Executive Committee Changes
The future executive committee of Siegfried will consist of seven members: Rudolf Hanko, CEO; Michael Hüsler, CFO; and Hanspeter Brun, Head of HR; will continue in the same function. Marianne Späne, formerly head of the Siegfried Generics division, will be responsible for Business Development and Sales. Hubert Stückler, formerly head of the Siegfried Actives division, will be responsible for the worldwide technical operations. Former chief communications officer, Peter Gehler, will head the Corporate Center, which includes communication, the legal department, facility management and the chairman's
office. In addition to his duties as CEO, Rudolf Hanko will assume responsibility for Research
& Development on an interim basis until the position of head of R&D is filled.

 

Company

Logo:

Siegfried

Untere Brühlstr. 4
4800 Zofingen
Switzerland

Company contact







Interview

The UK Chemical Supply Chain
Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.